Nicholas Investment Partners LP Invests $4.97 Million in Scholar Rock Holding Corporation $SRRK

Nicholas Investment Partners LP acquired a new stake in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 90,334 shares of the company’s stock, valued at approximately $4,968,000.

Several other hedge funds have also made changes to their positions in the stock. GAMMA Investing LLC raised its position in Scholar Rock by 20.8% in the second quarter. GAMMA Investing LLC now owns 1,406 shares of the company’s stock worth $77,000 after purchasing an additional 242 shares in the last quarter. Values First Advisors Inc. raised its holdings in shares of Scholar Rock by 1.5% in the 1st quarter. Values First Advisors Inc. now owns 18,850 shares of the company’s stock worth $927,000 after buying an additional 286 shares in the last quarter. IFP Advisors Inc raised its holdings in shares of Scholar Rock by 294.1% in the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after buying an additional 450 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Scholar Rock by 151.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after buying an additional 525 shares during the period. Finally, California State Teachers Retirement System lifted its position in shares of Scholar Rock by 0.9% during the 2nd quarter. California State Teachers Retirement System now owns 62,372 shares of the company’s stock worth $2,209,000 after buying an additional 577 shares during the period. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Price Performance

Scholar Rock stock opened at $58.20 on Tuesday. The business’s fifty day moving average is $52.10 and its two-hundred day moving average is $48.56. The company has a debt-to-equity ratio of 0.77, a quick ratio of 7.02 and a current ratio of 7.02. The firm has a market cap of $7.09 billion, a P/E ratio of -16.87 and a beta of 0.69. Scholar Rock Holding Corporation has a 52 week low of $27.07 and a 52 week high of $58.75.

Scholar Rock (NASDAQ:SRRK) last announced its earnings results on Thursday, August 6th. The company reported ($0.84) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.84). During the same period last year, the business earned ($0.98) earnings per share. Equities research analysts forecast that Scholar Rock Holding Corporation will post -3.23 earnings per share for the current fiscal year.

Insider Activity

In other Scholar Rock news, Director Katie Peng sold 5,446 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total value of $293,430.48. Following the completion of the transaction, the director directly owned 34,301 shares of the company’s stock, valued at approximately $1,848,137.88. The trade was a 13.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael Gilman sold 2,544 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $53.87, for a total transaction of $137,045.28. Following the completion of the transaction, the director directly owned 59,511 shares of the company’s stock, valued at approximately $3,205,857.57. This represents a 4.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 17,149 shares of company stock worth $923,108. 10.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on SRRK shares. Wedbush reaffirmed an “outperform” rating and issued a $64.00 price target on shares of Scholar Rock in a research note on Friday. BMO Capital Markets reiterated an “outperform” rating and set a $76.00 price objective on shares of Scholar Rock in a research note on Friday, August 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a report on Friday, July 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, June 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $65.00 target price on shares of Scholar Rock in a report on Monday, August 10th. Four analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $58.77.

Scholar Rock Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).